Phase 2 Sickle Cell Disease Trial, Recruiting NCT02447874 Sponsor: Emory University Condition: Sickle Cell Disease
Back to Sickle Cell Disease

Phase 2 Sickle Cell Disease Trial, Recruiting

NCT02447874
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with sickle cell disease, specifically the Hemoglobin SS (HbSS) or Sβ⁰-thalassemia type
  • You are between 7 and 21 years old
  • You weigh at least 25 kg (about 55 lbs)
  • You are currently in an acute care setting (such as an emergency room, hospital ward, or clinic) with pain from sickle cell disease that is severe enough to need pain medicine given through a needle or IV (not caused by something unrelated to sickle cell disease)

Who may not be able to join:

  • You are being sent home from the acute care setting rather than being kept for further treatment
  • You have a different type of sickle cell disease, such as HbSC, HbSD, HbSE, HbSO, Hb-Beta Thal, or you are an HbAS carrier
  • Your hemoglobin (red blood cell) level is very low (below 5 gm/dL)
  • You are expected to need a red blood cell transfusion right away
  • You have kidney problems above a certain level (confirm with trial site)
  • You are experiencing changes in your mental state or nervous system function
  • You are having or are suspected to be having a stroke
  • You are pregnant
  • You are allergic to arginine (a type of amino acid)
  • You were hospitalized less than 7 days ago
  • You have used inhaled nitric oxide, sildenafil, or arginine in the past 14 days
  • The doctor running the trial does not feel you are a suitable candidate for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Claudia Morris, MD, Emory University

Phone: 404-785-4525

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 May 2015
Est. completion
1 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pharmacokinetics of IV arginine, measured by plasma arginine concentration over time; Change in nitric oxide metabolites

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov